Video

Weighing the Risks and Benefits of Colorectal Cancer Treatment During the COVID-19 Pandemic

Despite the impact that COVID-19 is having on cancer treatment schedules, one expert stresses the importance of staying the course not just for an individual’s benefit, but for the health of others.

To comment on what he’s seeing in practice at the University of Colorado Cancer Center and in his work with the Colorectal Cancer Alliance, CURE® spoke with Dr. Christopher Lieu, who offered some tips on how patients with colorectal cancer can navigate the novel coronavirus crisis.

“What’s going on right now is completely unprecedented,” said Lieu. “We’re learning along with our patients more about the virus and how to combat it, and the impact of COVID-19 on our patients.”

In determining what’s best for each of his patients, Lieu explained that the conversations focus on risks of exposing patients to possible infection versus the benefits of treatment. But as he noted, “Cancer doesn’t care if there’s a pandemic or not. Cancer’s not going to stop just because we’re dealing with a pandemic and our patients understand that better than anybody.”

Despite the impact that COVID-19 is having on treatment schedules and the anxiety that self-imposed isolation can cause, Lieu stresses the importance of staying the course not just for an individual’s benefit, but for the health of others.

“The real take-home message here is that even if your risk for developing COVID-19 is really low, by doing some of these things, not only are you protecting yourself and those that are close to you, but you really could be saving the life of someone you’ve never met before,” said Lieu.

“If you think about it that way, it provides a lot of motivation to do these things and do them right.”

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.
Related Content